NPPA-AS1: A Potential Drug Target and Biomarker (G100379251)
NPPA-AS1: A Potential Drug Target and Biomarker
Non-Protein-Amino Acid-Containing Structures (NPAs) have been identified as potential drug targets in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most promising structures is the N-acylated small molecule, called NPPA-AS1, which has been shown to interact with several protein-protein interfaces and has been identified as a potential drug target in multiple diseases.
NPPA-AS1 is a small molecule that is derived from the amino acid Asp. It has a N-acylated side chain, which consists of an amino acid that is attached to the nitrogen atom of the side chain. The N-acylated side chain is a common structural feature that has been observed in various proteins, including enzymes, G-protein-coupled receptors, and other transmembrane proteins.
One of the unique features of NPPA-AS1 is its ability to interact with protein-protein interfaces. This interaction can lead to the formation of inclusion complexes, which can be stable and have been observed to affect protein function. NPPA-AS1 has been shown to interact with a variety of protein-protein interfaces, including those between the cytoskeleton and the endoplasmic reticulum, and between different cell types.
In addition to its ability to interact with protein-protein interfaces, NPPA-AS1 has also been shown to have a unique biological activity. Studies have shown that NPPA-AS1 can induce cell death in various cell types, including cancer cells, and that it can also inhibit the growth of cancer cells. This suggests that NPPA-AS1 may have a potential as a cancer therapeutic.
The N-acylated small molecule has also been identified as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that NPPA-AS1 may be a useful tool for the diagnosis and treatment of these diseases.
NPPA-AS1 has been shown to interact with several protein-protein interfaces, including those between the cytoskeleton and the endoplasmic reticulum. This interaction suggests that NPPA-AS1 may have a role in regulating cellular processes that are important for the cytoskeleton and the endoplasmic reticulum.
In addition to its potential role in cellular processes, NPPA-AS1 has also been shown to have a unique biological activity. Studies have shown that NPPA-AS1 can induce cell death in various cell types, including cancer cells, and that it can also inhibit the growth of cancer cells. This suggests that NPPA-AS1 may have a potential as a cancer therapeutic.
The N-acylated small molecule has also been identified as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that NPPA-AS1 may be a useful tool for the diagnosis and treatment of these diseases.
In conclusion, NPPA-AS1 is a small molecule that has been shown to interact with several protein-protein interfaces and has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further studies are needed to fully understand its unique biological activity and potential as a therapeutic.
Protein Name: NPPA Antisense RNA 1
The "NPPA-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPPA-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
NPPB | NPPC | NPR1 | NPR2 | NPR3 | NPRL2 | NPRL3 | NPS | NPSR1 | NPSR1-AS1 | NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R | NPY2R | NPY4R | NPY4R2 | NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS | NRSN1 | NRSN2 | NRSN2-AS1 | NRTN | NRXN1 | NRXN2 | NRXN2-AS1 | NRXN3 | NSA2 | NSA2P2 | NSD1 | NSD2 | NSD3
